NOTE 🌱 created from: Abemaciclb postmonarch switching CDKi at PD improve survival References postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. | Journal of Clinical Oncology
